🇺🇸 FDA
Patent

US 11447797

AAV with unique capsid protein VP1 and methods of using for treatment

granted A61PA61P5/14

Quick answer

US patent 11447797 (AAV with unique capsid protein VP1 and methods of using for treatment) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61P, A61P5/14